AI GTM Leader Clay Raises $100M Series C to Fuel GTM Engineering Roles Industrywide
5.8.2025 14:45:00 CEST | Business Wire | Press release
CapitalG leads round at $3.1B valuation as Clay’s AI platform scales new "GTM Engineer" role across tech industry
Clay, the leading AI go-to-market (GTM) development platform, today announced it has raised $100 million in Series C funding at a $3.1 billion post-money valuation, just six months after announcing its Series B expansion. The round was led by Alphabet’s independent growth fund, CapitalG, with participation from existing investors Sequoia Capital, Meritech Capital, First Round Capital, BoxGroup, and Boldstart, as well as new investor Sapphire Ventures. This brings the company’s total funding to $204 million.
Clay’s revenue is on track to more than triple this year, and its more than 10,000 customers include leading AI companies like OpenAI, Anthropic, and Cursor, as well as fast-growing companies like Canva, Intercom, and Rippling. Clay’s platform transforms traditional sales and marketing operations, building automated workflows that can research thousands of prospects, personalize outreach at scale, and identify revenue opportunities that would be impossible to find manually. It integrates with over 150 data sources, and its AI agents enable creative research like monitoring competitor mentions to trigger personalized campaigns or analyzing satellite imagery to count warehouse parking spots as a predictor of customer fit.
Clay is demonstrating that AI can be a job creator and has pioneered the creation of the GTM Engineering role, which, while only created two years ago, has already been adopted by leading companies. There are currently over 280 GTM Engineer positions posted in companies like Cursor, Webflow, Notion, and Lovable. Furthermore, GTM engineers have built standalone million-dollar agencies, and seven independent bootcamps teaching GTM engineering skills have graduated over 2,500 students. Clay's community spans 60 clubs across 30 countries, with particularly strong growth in developing markets like India and Pakistan. The company is on track to generate $50 million in revenue for its data and integration partners in 2025, while its ecosystem of 108 agencies worldwide represents hundreds of millions in collective revenue.
"GTM engineering represents the first true AI-native profession, and we believe that it will be tech’s next big job category," said Kareem Amin, CEO and co-founder of Clay. "These professionals earn a median salary of $160,000 – about 20% more than traditional sales ops roles – and can make entire sales teams dramatically more effective without requiring a computer science degree. At a time when there’s a lot of anxiety about the potential for AI to take jobs, we’re honored to be pioneering a soon-to-be ubiquitous role that shows how AI creates jobs."
“Clay fights AI spam with precision. While some may worry that AI may create more generic outreach, our customers are using AI to send fewer, dramatically better messages," said Varun Anand, Clay co-founder. “Traditional sales teams face a choice between high volume or high quality. Clay's AI research agent – which has completed over 1 billion tasks – enables both.”
“Clay is the first and only company to take an engineering approach to go-to-market, building a platform that allows sales and marketing teams to bring to life workflows that they could only dream of before. After speaking with over 100 sales and marketing leaders, it is clear that Clay is setting the bar for how leading organizations use AI for sales and marketing” said Jane Alexander, partner at CapitalG. “We are honored to partner with Kareem, Varun, and team on their journey to make Clay the definitive GTM platform for the AI era.”
The funding will be used to accelerate Clay's product development and to help support the roll out of GTM engineering as a career path. “We're fostering an entire economic ecosystem," said Amin. "Our goal is to democratize the ability to build scalable revenue systems, regardless of technical background."
About Clay
Founded in 2017 by Kareem Amin and joined by co-founder Varun Anand in 2021, Clay is the leading GTM development platform that helps companies turn growth ideas into reality using AI and automation. The platform combines data from 150+ sources with AI research capabilities to enable personalized outreach at scale. Clay is headquartered in New York and serves over 10,000 customers worldwide. Learn more at https://www.clay.com/.
About CapitalG
CapitalG, Alphabet's independent growth fund, invests in generational companies transforming the fields of enterprise infrastructure, security, and data; fintech; and consumer services and marketplaces. CapitalG is honored to support generational companies like Abridge, CrowdStrike, Databricks, Duolingo, Freshworks, Gusto, Monzo, Stripe, and UiPath. https://capitalg.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20250805719448/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom